Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection

被引:17
|
作者
Sharma, Yeshika [1 ]
Weaver, Michael J. [1 ]
Ludwig, Daniel R. [2 ]
Fowler, Kathryn [2 ]
Vachharajani, Neeta [3 ]
Chapman, William C. [3 ]
Crippin, Jeffrey S. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
关键词
CHRONIC HEPATITIS-C; HEPATECTOMY; PROGNOSIS; RISK;
D O I
10.1016/j.surg.2017.10.063
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Alpha-fetoprotein has been used as a predictor of recurrence for hepatocellular carcinoma and disease-free survival post-resection. Studies in East Asia have shown that serum alpha-fetoprotein per total tumor volume ratio is a better prognostic indicator than alpha-fetoprotein alone. Similar studies in the United States evaluating serum alpha-fetoprotein to total tumor volume ratio have not been conducted. Its relevance is incompletely understood. Methods: Consecutive patients undergoing resection for hepatocellular carcinoma at a single tertiary center between 2000 and 2013 were identified for inclusion in this retrospective cohort study. Patient demographics, associated liver disease, Child-Pugh and Model for End-Stage Liver Disease scores, preoperative imaging, surgical pathology, alpha-fetoprotein at diagnosis, last alpha-fetoprotein before surgery, and peak alpha-fetoprotein levels were recorded. Actual tumor volume by imaging volumetrics was used when available (n = 70). For the remaining cases, total tumor volume was calculated using the sum of the volumes of all the tumors ((4/3)pi r(3)) where "r" is the mean radius of each lesion. Peak serum alpha-fetoprotein was used to calculate the alpha-fetoprotein to total tumor volume ratio. Results: A total of 124 patients resected for hepatocellular carcinoma between 2000 and 2013 were identified. Overall 1-, 3-, and 5-year survival post resection was 76%, 53%, and 35%, respectively. On multivariate analysis, peak alpha-fetoprotein to total tumor volume ratio > 20 (P < .001, HR = 3.72, 95% CI [1.82-7.58]) and lymphovascular space invasion (P=.002, HR=3.30, 95% CI [1.57-6.94]) were found to affect hepatocellular carcinoma recurrence-free survival. Conclusion: A variety of prognostic values predict the recurrence of hepatocellular carcinoma postresection. Peak preoperative alpha-fetoprotein to total tumor volume > 20 and lymphovascular space invasion has been shown to predict recurrence of hepatocellular carcinoma. Our study confirms findings from East Asian studies. But larger series are needed to establish this correlation in patients with hepatocellular carcinoma not treated by resection. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:1002 / 1007
页数:6
相关论文
共 50 条
  • [21] Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection
    Rungsakulkij, Narongsak
    Suragul, Wikran
    Mingphruedhi, Somkit
    Tangtawee, Pongsatorn
    Muangkaew, Paramin
    Aeesoa, Suraida
    WORLD JOURNAL OF CLINICAL CASES, 2018, 6 (06) : 110 - 120
  • [22] Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection
    Narongsak Rungsakulkij
    Wikran Suragul
    Somkit Mingphruedhi
    Pongsatorn Tangtawee
    Paramin Muangkaew
    Suraida Aeesoa
    World Journal of Clinical Cases, 2018, (06) : 110 - 120
  • [23] ELEVATION OF ALPHA-FETOPROTEIN LEVEL WITHOUT EVIDENCE OF RECURRENCE AFTER HEPATECTOMY FOR HEPATOCELLULAR-CARCINOMA
    EZAKI, T
    YUKAYA, H
    OGAWA, Y
    CHANG, YC
    NAGASUE, N
    CANCER, 1988, 61 (09) : 1880 - 1883
  • [24] Half-Life of Serum Alpha-Fetoprotein An Early Prognostic Index of Recurrence and Survival After Hepatic Resection for Hepatocellular Carcinoma
    Shim, Ju Hyun
    Han, Seungbong
    Lee, Young-Joo
    Lee, Sung-Gyu
    Kim, Kang Mo
    Lim, Young-Suk
    Chung, Young-Hwa
    Lee, Yung Sang
    Lee, Han Chu
    ANNALS OF SURGERY, 2013, 257 (04) : 708 - 717
  • [25] Alpha-fetoprotein Level Predicts Recurrence Post Liver Transplant for Hepatocellular Carcinoma
    Huang, D.
    Lim, K.
    Shridhar, I.
    Kow, A.
    Bonney, G.
    Dan, Y. Y.
    Lee, G. H.
    Lee, Y. M.
    Lim, S. G.
    Low, H. C.
    Krishnakumar, M.
    Tan, P. S.
    TRANSPLANTATION, 2017, 101 (05) : 227 - 228
  • [26] Clinical Significance of Alpha-Fetoprotein in Alpha-Fetoprotein Negative Hepatocellular Carcinoma Underwent Curative Resection
    Lin, Kongying
    Huang, Qizhen
    Zeng, Jianxing
    Ding, Zongren
    Wang, Lei
    Chen, Zhenwei
    Guo, Pengfei
    Zeng, Yongyi
    Zhou, Weiping
    Liu, Jingfeng
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (12) : 4545 - 4556
  • [27] Clinical Significance of Alpha-Fetoprotein in Alpha-Fetoprotein Negative Hepatocellular Carcinoma Underwent Curative Resection
    Kongying Lin
    Qizhen Huang
    Jianxing Zeng
    Zongren Ding
    Lei Wang
    Zhenwei Chen
    Pengfei Guo
    Yongyi Zeng
    Weiping Zhou
    Jingfeng Liu
    Digestive Diseases and Sciences, 2021, 66 : 4545 - 4556
  • [28] INCREASED ALPHA-FETOPROTEIN AFTER BRIDGE THERAPIES AS PREDICTOR OF RECURRENCE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH LIVER TRANSPLANTATION
    Lai, Quirino
    Avolio, Alfonso W.
    Manzia, Tommaso M.
    Agnes, Salvatore
    Tisone, Giuseppe
    Berloco, Pasquale B.
    Rossi, Massimo
    TRANSPLANT INTERNATIONAL, 2011, 24 : 3 - 3
  • [29] Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation
    Siripongsakun, Surachate
    Wei, Sindy H.
    Lin, Stephanie
    Chen, Jeffrey
    Raman, Steven S.
    Sayre, James
    Tong, Myron J.
    Lu, David S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (01) : 157 - 164
  • [30] Alpha-Fetoprotein at Time of Recurrence Predicts Post-Recurrence Outcomes Following Resection of Hepatocellular Carcinoma
    Tsilimigras, D. I.
    Hyer, M.
    Bagante, F.
    Moris, D.
    Ratti, F.
    Marques, H.
    Soubrane, O.
    Lam, V.
    Poultsides, G.
    Popescu, I.
    Alexandrescu, S.
    Martel, G.
    Workneh, A.
    Guglielmi, A.
    Hugh, T.
    Aldrighetti, L.
    Endo, I.
    Pawlik, T. M.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S20 - S20